David Murphy
Concepts (415)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intensive Care Units | 29 | 2026 | 923 | 4.980 |
Why?
| | Critical Care | 12 | 2026 | 700 | 2.770 |
Why?
| | Critical Illness | 15 | 2026 | 905 | 2.220 |
Why?
| | Erythrocyte Transfusion | 6 | 2019 | 225 | 1.950 |
Why?
| | Organ Dysfunction Scores | 4 | 2023 | 55 | 1.450 |
Why?
| | Health Resources | 3 | 2016 | 130 | 1.230 |
Why?
| | Hospital Mortality | 13 | 2026 | 1037 | 1.060 |
Why?
| | Quality Indicators, Health Care | 3 | 2026 | 340 | 1.020 |
Why?
| | Sepsis | 9 | 2026 | 668 | 1.010 |
Why?
| | Pneumonia, Ventilator-Associated | 2 | 2018 | 58 | 0.980 |
Why?
| | Delphi Technique | 3 | 2025 | 347 | 0.900 |
Why?
| | Common Data Elements | 1 | 2025 | 18 | 0.870 |
Why?
| | Brain Diseases | 5 | 2024 | 157 | 0.860 |
Why?
| | Cross Infection | 4 | 2026 | 258 | 0.840 |
Why?
| | Quality Improvement | 4 | 2026 | 1325 | 0.830 |
Why?
| | Neurodevelopmental Disorders | 5 | 2026 | 234 | 0.830 |
Why?
| | Wounds and Injuries | 3 | 2025 | 956 | 0.780 |
Why?
| | Multiple Organ Failure | 3 | 2019 | 122 | 0.730 |
Why?
| | Computed Tomography Angiography | 4 | 2017 | 151 | 0.700 |
Why?
| | Fluid Therapy | 3 | 2024 | 152 | 0.670 |
Why?
| | Humans | 100 | 2026 | 145625 | 0.660 |
Why?
| | Bacterial Infections | 2 | 2021 | 246 | 0.640 |
Why?
| | Coronary Artery Disease | 5 | 2019 | 751 | 0.630 |
Why?
| | Spastic Paraplegia, Hereditary | 3 | 2026 | 13 | 0.610 |
Why?
| | Radiation Dosage | 2 | 2020 | 193 | 0.600 |
Why?
| | Health Care Costs | 3 | 2020 | 418 | 0.600 |
Why?
| | Coronary Angiography | 4 | 2017 | 325 | 0.590 |
Why?
| | Catheter-Related Infections | 3 | 2026 | 98 | 0.580 |
Why?
| | Survivors | 1 | 2023 | 521 | 0.570 |
Why?
| | Movement Disorders | 3 | 2024 | 68 | 0.560 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2019 | 77 | 0.560 |
Why?
| | Catheterization, Central Venous | 3 | 2026 | 120 | 0.550 |
Why?
| | Systemic Inflammatory Response Syndrome | 2 | 2022 | 96 | 0.540 |
Why?
| | Phenotype | 13 | 2026 | 3186 | 0.520 |
Why?
| | Ventilators, Mechanical | 2 | 2020 | 70 | 0.520 |
Why?
| | Ventricular Outflow Obstruction | 1 | 2017 | 38 | 0.510 |
Why?
| | Mitral Valve Insufficiency | 1 | 2017 | 69 | 0.500 |
Why?
| | Mitral Valve | 1 | 2017 | 96 | 0.500 |
Why?
| | Respiration, Artificial | 4 | 2026 | 711 | 0.500 |
Why?
| | Hip Fractures | 1 | 2018 | 88 | 0.490 |
Why?
| | Blood Transfusion | 2 | 2018 | 393 | 0.490 |
Why?
| | Hemoglobins | 6 | 2019 | 384 | 0.480 |
Why?
| | Intellectual Disability | 5 | 2026 | 178 | 0.480 |
Why?
| | Practice Patterns, Physicians' | 3 | 2021 | 1370 | 0.480 |
Why?
| | Physician Incentive Plans | 1 | 2016 | 8 | 0.470 |
Why?
| | Middle Aged | 36 | 2026 | 36359 | 0.460 |
Why?
| | United States Public Health Service | 1 | 2015 | 8 | 0.460 |
Why?
| | Albumins | 1 | 2016 | 119 | 0.460 |
Why?
| | Pneumonia, Viral | 4 | 2020 | 387 | 0.440 |
Why?
| | Female | 49 | 2026 | 79080 | 0.440 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2017 | 196 | 0.440 |
Why?
| | Hospitals | 2 | 2020 | 730 | 0.430 |
Why?
| | Male | 49 | 2026 | 73014 | 0.430 |
Why?
| | Radiology | 1 | 2017 | 175 | 0.420 |
Why?
| | Emergencies | 1 | 2015 | 173 | 0.420 |
Why?
| | Loss of Function Mutation | 2 | 2026 | 47 | 0.410 |
Why?
| | Lung Diseases | 2 | 2024 | 787 | 0.410 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 1194 | 0.400 |
Why?
| | Severity of Illness Index | 7 | 2026 | 2910 | 0.400 |
Why?
| | Cardiac Catheterization | 1 | 2017 | 569 | 0.390 |
Why?
| | Positron Emission Tomography Computed Tomography | 4 | 2025 | 122 | 0.390 |
Why?
| | Cardiomyopathies | 1 | 2017 | 339 | 0.380 |
Why?
| | Developmental Disabilities | 3 | 2024 | 280 | 0.380 |
Why?
| | Guideline Adherence | 3 | 2016 | 585 | 0.370 |
Why?
| | Medication Therapy Management | 2 | 2025 | 73 | 0.370 |
Why?
| | Aged | 26 | 2026 | 26251 | 0.360 |
Why?
| | Microcephaly | 2 | 2024 | 105 | 0.360 |
Why?
| | Evidence-Based Medicine | 2 | 2013 | 727 | 0.360 |
Why?
| | Data Collection | 1 | 2015 | 647 | 0.350 |
Why?
| | Retrospective Studies | 19 | 2026 | 17291 | 0.350 |
Why?
| | Emergency Medical Services | 2 | 2016 | 680 | 0.350 |
Why?
| | Evidence-Based Practice | 1 | 2014 | 230 | 0.350 |
Why?
| | APACHE | 4 | 2026 | 67 | 0.330 |
Why?
| | Coronavirus Infections | 3 | 2020 | 379 | 0.330 |
Why?
| | Urinary Tract Infections | 2 | 2026 | 207 | 0.330 |
Why?
| | Mitochondrial Diseases | 2 | 2022 | 94 | 0.330 |
Why?
| | Hospitalization | 7 | 2022 | 2468 | 0.330 |
Why?
| | Membrane Proteins | 4 | 2026 | 1130 | 0.320 |
Why?
| | Consensus | 3 | 2025 | 465 | 0.320 |
Why?
| | Societies, Hospital | 1 | 2010 | 1 | 0.320 |
Why?
| | Water-Electrolyte Imbalance | 2 | 2025 | 38 | 0.320 |
Why?
| | Aged, 80 and over | 10 | 2021 | 8351 | 0.310 |
Why?
| | Tomography, X-Ray Computed | 4 | 2024 | 2766 | 0.310 |
Why?
| | Adult | 26 | 2026 | 40821 | 0.300 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2674 | 0.300 |
Why?
| | Epilepsy | 2 | 2023 | 397 | 0.270 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2009 | 100 | 0.270 |
Why?
| | Pedigree | 6 | 2026 | 507 | 0.270 |
Why?
| | Delivery of Health Care | 1 | 2015 | 942 | 0.270 |
Why?
| | Infection Control | 4 | 2026 | 174 | 0.260 |
Why?
| | Betacoronavirus | 2 | 2020 | 288 | 0.260 |
Why?
| | Machine Learning | 4 | 2026 | 590 | 0.250 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2025 | 165 | 0.250 |
Why?
| | Hospital Costs | 2 | 2019 | 127 | 0.240 |
Why?
| | Mutation | 10 | 2026 | 4082 | 0.240 |
Why?
| | Maryland | 2 | 2018 | 67 | 0.230 |
Why?
| | Parkinsonian Disorders | 1 | 2026 | 43 | 0.230 |
Why?
| | Genetic Heterogeneity | 1 | 2026 | 66 | 0.230 |
Why?
| | Acute Lung Injury | 1 | 2009 | 311 | 0.230 |
Why?
| | United States | 16 | 2021 | 16041 | 0.230 |
Why?
| | Electronic Health Records | 5 | 2024 | 1208 | 0.230 |
Why?
| | Catechol O-Methyltransferase | 1 | 2025 | 20 | 0.220 |
Why?
| | Mediator Complex | 2 | 2023 | 61 | 0.220 |
Why?
| | Quality of Health Care | 3 | 2021 | 692 | 0.220 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2026 | 155 | 0.220 |
Why?
| | Length of Stay | 3 | 2025 | 1342 | 0.220 |
Why?
| | Birt-Hogg-Dube Syndrome | 2 | 2024 | 9 | 0.220 |
Why?
| | Unsupervised Machine Learning | 1 | 2025 | 23 | 0.210 |
Why?
| | Pneumonia | 2 | 2010 | 633 | 0.210 |
Why?
| | Patient Satisfaction | 1 | 2009 | 698 | 0.210 |
Why?
| | Coronary Vessels | 2 | 2016 | 245 | 0.200 |
Why?
| | Kidney Neoplasms | 2 | 2020 | 417 | 0.200 |
Why?
| | Congenital Disorders of Glycosylation | 1 | 2023 | 17 | 0.200 |
Why?
| | Epilepsy, Generalized | 1 | 2023 | 24 | 0.200 |
Why?
| | Nervous System Malformations | 1 | 2024 | 46 | 0.200 |
Why?
| | Cysts | 1 | 2024 | 108 | 0.200 |
Why?
| | Intra-Abdominal Fat | 1 | 2024 | 101 | 0.200 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2025 | 100 | 0.200 |
Why?
| | Prognosis | 3 | 2023 | 4331 | 0.200 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2024 | 91 | 0.200 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2023 | 46 | 0.200 |
Why?
| | Hearing Loss | 1 | 2026 | 177 | 0.190 |
Why?
| | Membrane Transport Proteins | 1 | 2024 | 153 | 0.190 |
Why?
| | Resuscitation | 2 | 2024 | 314 | 0.190 |
Why?
| | Systems Analysis | 1 | 2023 | 25 | 0.190 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2024 | 150 | 0.190 |
Why?
| | Abnormalities, Multiple | 1 | 2024 | 193 | 0.190 |
Why?
| | Cell Division | 1 | 2024 | 735 | 0.190 |
Why?
| | Sarcoidosis | 1 | 2025 | 164 | 0.190 |
Why?
| | Child, Preschool | 11 | 2026 | 11888 | 0.180 |
Why?
| | Dystonia | 1 | 2022 | 27 | 0.180 |
Why?
| | Information Dissemination | 1 | 2025 | 224 | 0.180 |
Why?
| | Neural Stem Cells | 1 | 2024 | 167 | 0.180 |
Why?
| | Pandemics | 5 | 2021 | 1700 | 0.180 |
Why?
| | Pharmacists | 2 | 2022 | 260 | 0.180 |
Why?
| | ADAM Proteins | 1 | 2022 | 65 | 0.180 |
Why?
| | Apyrase | 1 | 2022 | 27 | 0.180 |
Why?
| | Neuroendocrine Cells | 1 | 2022 | 34 | 0.180 |
Why?
| | Parkinson Disease | 2 | 2026 | 614 | 0.180 |
Why?
| | Patient Safety | 1 | 2026 | 351 | 0.180 |
Why?
| | Connective Tissue Diseases | 1 | 2022 | 85 | 0.180 |
Why?
| | beta Karyopherins | 1 | 2021 | 9 | 0.170 |
Why?
| | Resource Allocation | 1 | 2021 | 45 | 0.170 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2024 | 269 | 0.170 |
Why?
| | Community Pharmacy Services | 1 | 2021 | 46 | 0.170 |
Why?
| | Pharmacy | 1 | 2021 | 32 | 0.170 |
Why?
| | ROC Curve | 1 | 2023 | 613 | 0.170 |
Why?
| | Loss of Heterozygosity | 1 | 2021 | 51 | 0.170 |
Why?
| | Infant | 9 | 2026 | 10093 | 0.170 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2021 | 26 | 0.170 |
Why?
| | Calcium-Binding Proteins | 1 | 2022 | 219 | 0.170 |
Why?
| | Tetraspanins | 1 | 2021 | 19 | 0.170 |
Why?
| | Pharmaceutical Services | 1 | 2021 | 76 | 0.160 |
Why?
| | Hair Cells, Auditory, Inner | 1 | 2021 | 17 | 0.160 |
Why?
| | Cataract | 1 | 2023 | 238 | 0.160 |
Why?
| | Multimorbidity | 1 | 2021 | 65 | 0.160 |
Why?
| | Cannula | 1 | 2020 | 29 | 0.160 |
Why?
| | Health Care Surveys | 2 | 2014 | 538 | 0.160 |
Why?
| | Pharmacy Service, Hospital | 1 | 2021 | 90 | 0.160 |
Why?
| | Pneumonia, Bacterial | 1 | 2021 | 114 | 0.160 |
Why?
| | Chest Pain | 1 | 2021 | 100 | 0.160 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2021 | 66 | 0.160 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 147 | 0.160 |
Why?
| | Retinal Diseases | 1 | 2021 | 101 | 0.160 |
Why?
| | Pneumothorax | 1 | 2020 | 54 | 0.160 |
Why?
| | Pleural Effusion | 1 | 2021 | 59 | 0.150 |
Why?
| | Drug Resistant Epilepsy | 1 | 2022 | 144 | 0.150 |
Why?
| | White Matter | 1 | 2022 | 169 | 0.150 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2024 | 300 | 0.150 |
Why?
| | Point Mutation | 1 | 2021 | 232 | 0.150 |
Why?
| | Amino Acid Substitution | 1 | 2021 | 295 | 0.150 |
Why?
| | Immunomodulation | 1 | 2020 | 98 | 0.150 |
Why?
| | Genetic Predisposition to Disease | 2 | 2026 | 2455 | 0.150 |
Why?
| | Prospective Studies | 6 | 2021 | 8087 | 0.150 |
Why?
| | Coinfection | 1 | 2021 | 143 | 0.150 |
Why?
| | Medical Overuse | 1 | 2020 | 30 | 0.150 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2019 | 30 | 0.150 |
Why?
| | DNA, Mitochondrial | 1 | 2021 | 212 | 0.150 |
Why?
| | Urinalysis | 1 | 2020 | 82 | 0.150 |
Why?
| | Quality Assurance, Health Care | 3 | 2010 | 339 | 0.150 |
Why?
| | Hematocrit | 1 | 2019 | 108 | 0.150 |
Why?
| | Aortic Aneurysm, Thoracic | 1 | 2021 | 135 | 0.150 |
Why?
| | Risk Factors | 7 | 2021 | 10840 | 0.150 |
Why?
| | Socioenvironmental Therapy | 1 | 2019 | 2 | 0.150 |
Why?
| | Nuclear Proteins | 1 | 2024 | 739 | 0.150 |
Why?
| | DNA Methylation | 1 | 2024 | 721 | 0.150 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2019 | 74 | 0.140 |
Why?
| | Health Equity | 1 | 2021 | 139 | 0.140 |
Why?
| | Syndrome | 3 | 2026 | 377 | 0.140 |
Why?
| | Economics, Hospital | 1 | 2019 | 28 | 0.140 |
Why?
| | Cohort Studies | 6 | 2026 | 6045 | 0.140 |
Why?
| | Dyspnea | 1 | 2021 | 251 | 0.140 |
Why?
| | Zebrafish | 4 | 2026 | 533 | 0.140 |
Why?
| | Follow-Up Studies | 3 | 2023 | 5397 | 0.140 |
Why?
| | Nerve Tissue Proteins | 1 | 2022 | 594 | 0.140 |
Why?
| | Diagnostic Techniques and Procedures | 1 | 2018 | 19 | 0.140 |
Why?
| | Weight Loss | 1 | 2024 | 857 | 0.140 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2020 | 189 | 0.140 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2019 | 133 | 0.140 |
Why?
| | New Jersey | 1 | 2018 | 17 | 0.140 |
Why?
| | Adolescent | 11 | 2026 | 22451 | 0.140 |
Why?
| | Clinical Protocols | 2 | 2017 | 279 | 0.140 |
Why?
| | Academic Medical Centers | 3 | 2022 | 560 | 0.130 |
Why?
| | Kentucky | 1 | 2018 | 43 | 0.130 |
Why?
| | Nutrition Assessment | 1 | 2018 | 90 | 0.130 |
Why?
| | Artificial Intelligence | 1 | 2023 | 385 | 0.130 |
Why?
| | Bacteremia | 2 | 2010 | 218 | 0.130 |
Why?
| | Medical Audit | 2 | 2017 | 77 | 0.130 |
Why?
| | Anemia | 1 | 2019 | 189 | 0.130 |
Why?
| | Plasma | 1 | 2019 | 222 | 0.130 |
Why?
| | Acute Coronary Syndrome | 2 | 2019 | 299 | 0.130 |
Why?
| | Nervous System Diseases | 1 | 2021 | 286 | 0.130 |
Why?
| | Early Detection of Cancer | 1 | 2023 | 501 | 0.130 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 328 | 0.130 |
Why?
| | Washington | 1 | 2018 | 157 | 0.130 |
Why?
| | Hematologic Neoplasms | 1 | 2019 | 169 | 0.130 |
Why?
| | Clinical Decision-Making | 1 | 2021 | 364 | 0.130 |
Why?
| | Hospitals, University | 1 | 2017 | 176 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2024 | 1754 | 0.130 |
Why?
| | Preoperative Period | 1 | 2017 | 150 | 0.130 |
Why?
| | Shock, Hemorrhagic | 1 | 2019 | 195 | 0.130 |
Why?
| | Lung Diseases, Interstitial | 2 | 2024 | 677 | 0.120 |
Why?
| | Alleles | 3 | 2026 | 900 | 0.120 |
Why?
| | Child | 10 | 2026 | 22638 | 0.120 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2016 | 21 | 0.120 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 1156 | 0.120 |
Why?
| | Drug Utilization Review | 1 | 2016 | 60 | 0.120 |
Why?
| | Arteritis | 1 | 2016 | 23 | 0.120 |
Why?
| | Cost Savings | 1 | 2016 | 85 | 0.120 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2019 | 265 | 0.120 |
Why?
| | Embolism | 1 | 2016 | 49 | 0.110 |
Why?
| | Residence Characteristics | 1 | 2019 | 385 | 0.110 |
Why?
| | Animals | 11 | 2026 | 38030 | 0.110 |
Why?
| | Fracture Fixation, Internal | 1 | 2018 | 214 | 0.110 |
Why?
| | Heart Neoplasms | 1 | 2015 | 56 | 0.110 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2018 | 187 | 0.110 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2016 | 119 | 0.110 |
Why?
| | Respiratory Insufficiency | 2 | 2020 | 330 | 0.110 |
Why?
| | Burns | 1 | 2019 | 365 | 0.110 |
Why?
| | Aortic Diseases | 1 | 2016 | 124 | 0.110 |
Why?
| | Patient Outcome Assessment | 1 | 2015 | 128 | 0.110 |
Why?
| | Shock | 1 | 2015 | 99 | 0.100 |
Why?
| | Interdisciplinary Communication | 1 | 2015 | 200 | 0.100 |
Why?
| | Baltimore | 1 | 2014 | 71 | 0.100 |
Why?
| | Regression Analysis | 1 | 2016 | 994 | 0.100 |
Why?
| | Georgia | 2 | 2026 | 79 | 0.100 |
Why?
| | Practice Guidelines as Topic | 3 | 2021 | 1581 | 0.100 |
Why?
| | Medical Staff, Hospital | 1 | 2014 | 80 | 0.100 |
Why?
| | Drosophila melanogaster | 2 | 2026 | 237 | 0.100 |
Why?
| | Injury Severity Score | 1 | 2015 | 571 | 0.100 |
Why?
| | Health Services Needs and Demand | 1 | 2015 | 283 | 0.100 |
Why?
| | Time Factors | 3 | 2022 | 7079 | 0.100 |
Why?
| | Brain Injuries, Traumatic | 1 | 2019 | 459 | 0.100 |
Why?
| | Carcinoma, Renal Cell | 1 | 2015 | 229 | 0.100 |
Why?
| | Aorta | 1 | 2016 | 440 | 0.090 |
Why?
| | Confidence Intervals | 1 | 2013 | 328 | 0.090 |
Why?
| | Genes, Recessive | 2 | 2024 | 77 | 0.090 |
Why?
| | Young Adult | 7 | 2025 | 14240 | 0.090 |
Why?
| | Age Factors | 2 | 2017 | 3321 | 0.090 |
Why?
| | Acidosis | 1 | 2013 | 105 | 0.090 |
Why?
| | Treatment Outcome | 4 | 2020 | 11744 | 0.090 |
Why?
| | Atrophy | 2 | 2023 | 199 | 0.090 |
Why?
| | Organizational Culture | 2 | 2010 | 159 | 0.090 |
Why?
| | Paraplegia | 2 | 2022 | 60 | 0.090 |
Why?
| | Thrombosis | 1 | 2016 | 397 | 0.090 |
Why?
| | Nursing Staff, Hospital | 1 | 2014 | 145 | 0.090 |
Why?
| | Telemedicine | 1 | 2021 | 956 | 0.090 |
Why?
| | Autoimmune Diseases | 1 | 2016 | 466 | 0.090 |
Why?
| | Immunoglobulin G | 1 | 2016 | 899 | 0.090 |
Why?
| | Anti-Bacterial Agents | 2 | 2020 | 1935 | 0.080 |
Why?
| | Program Evaluation | 1 | 2016 | 945 | 0.080 |
Why?
| | Patient Discharge | 1 | 2018 | 991 | 0.080 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2013 | 293 | 0.080 |
Why?
| | Odds Ratio | 1 | 2013 | 1070 | 0.080 |
Why?
| | Obesity | 1 | 2024 | 3123 | 0.080 |
Why?
| | Disease Models, Animal | 3 | 2026 | 4565 | 0.080 |
Why?
| | Diet | 1 | 2018 | 1271 | 0.080 |
Why?
| | Glucocorticoids | 2 | 2019 | 536 | 0.080 |
Why?
| | Primary Health Care | 1 | 2021 | 1768 | 0.080 |
Why?
| | Arthritis, Rheumatoid | 1 | 2019 | 1184 | 0.080 |
Why?
| | Checklist | 1 | 2010 | 105 | 0.070 |
Why?
| | Mice | 5 | 2026 | 18266 | 0.070 |
Why?
| | Fibroblasts | 2 | 2026 | 1033 | 0.070 |
Why?
| | Safety Management | 1 | 2010 | 130 | 0.070 |
Why?
| | Medical Errors | 1 | 2009 | 124 | 0.070 |
Why?
| | Myocardial Infarction | 1 | 2016 | 1212 | 0.070 |
Why?
| | Cardiac Surgical Procedures | 1 | 2014 | 608 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2016 | 1403 | 0.070 |
Why?
| | Health Services Research | 1 | 2010 | 389 | 0.070 |
Why?
| | Mitochondria | 2 | 2026 | 996 | 0.060 |
Why?
| | Lung | 1 | 2020 | 4119 | 0.060 |
Why?
| | Cardiovascular Diseases | 1 | 2019 | 2218 | 0.060 |
Why?
| | Brain | 3 | 2024 | 2981 | 0.060 |
Why?
| | Workload | 1 | 2009 | 169 | 0.060 |
Why?
| | Biomarkers | 1 | 2018 | 4329 | 0.060 |
Why?
| | Decision Making | 1 | 2014 | 987 | 0.060 |
Why?
| | Connexin 26 | 1 | 2026 | 9 | 0.060 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2026 | 74 | 0.060 |
Why?
| | Longitudinal Studies | 1 | 2013 | 3005 | 0.060 |
Why?
| | Oregon | 1 | 2025 | 83 | 0.060 |
Why?
| | North Carolina | 1 | 2025 | 127 | 0.060 |
Why?
| | Emergency Service, Hospital | 1 | 2017 | 2357 | 0.060 |
Why?
| | Anti-Inflammatory Agents | 1 | 2008 | 473 | 0.050 |
Why?
| | Ethanolamine | 1 | 2024 | 6 | 0.050 |
Why?
| | Mutation, Missense | 1 | 2026 | 331 | 0.050 |
Why?
| | Genes, Dominant | 1 | 2024 | 94 | 0.050 |
Why?
| | N-Terminal Acetyltransferase F | 1 | 2024 | 1 | 0.050 |
Why?
| | Sodium-Phosphate Cotransporter Proteins, Type III | 1 | 2024 | 5 | 0.050 |
Why?
| | Proof of Concept Study | 1 | 2024 | 89 | 0.050 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2024 | 36 | 0.050 |
Why?
| | Lymphangioleiomyomatosis | 1 | 2024 | 37 | 0.050 |
Why?
| | Receptors, Virus | 1 | 2024 | 91 | 0.050 |
Why?
| | Guanine Nucleotide Exchange Factors | 1 | 2024 | 64 | 0.050 |
Why?
| | Inheritance Patterns | 1 | 2024 | 47 | 0.050 |
Why?
| | Radiopharmaceuticals | 1 | 2025 | 210 | 0.050 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2024 | 135 | 0.050 |
Why?
| | Rats | 2 | 2022 | 5574 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2024 | 312 | 0.050 |
Why?
| | Cell Polarity | 1 | 2024 | 137 | 0.050 |
Why?
| | Choline | 1 | 2024 | 134 | 0.050 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2024 | 115 | 0.050 |
Why?
| | Tremor | 1 | 2024 | 98 | 0.050 |
Why?
| | Propensity Score | 1 | 2025 | 370 | 0.050 |
Why?
| | Acetylation | 1 | 2024 | 262 | 0.050 |
Why?
| | Glycosylation | 1 | 2023 | 175 | 0.050 |
Why?
| | Phosphates | 1 | 2024 | 175 | 0.050 |
Why?
| | Drosophila Proteins | 1 | 2025 | 207 | 0.050 |
Why?
| | Vesicular Monoamine Transport Proteins | 1 | 2022 | 9 | 0.050 |
Why?
| | Spectrin | 1 | 2022 | 13 | 0.050 |
Why?
| | Supraoptic Nucleus | 1 | 2022 | 5 | 0.050 |
Why?
| | Neurogenesis | 1 | 2024 | 158 | 0.050 |
Why?
| | Disks Large Homolog 4 Protein | 1 | 2022 | 19 | 0.050 |
Why?
| | Amines | 1 | 2022 | 40 | 0.050 |
Why?
| | Ataxia | 1 | 2022 | 69 | 0.050 |
Why?
| | Dysarthria | 1 | 2022 | 10 | 0.050 |
Why?
| | Proteostasis | 1 | 2022 | 32 | 0.040 |
Why?
| | Nervous System | 1 | 2022 | 68 | 0.040 |
Why?
| | Homozygote | 1 | 2022 | 196 | 0.040 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2022 | 134 | 0.040 |
Why?
| | Cerebellum | 1 | 2023 | 225 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2023 | 494 | 0.040 |
Why?
| | Incidence | 2 | 2019 | 2910 | 0.040 |
Why?
| | Repressor Proteins | 1 | 2024 | 428 | 0.040 |
Why?
| | Mortality | 2 | 2017 | 375 | 0.040 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2008 | 926 | 0.040 |
Why?
| | Consanguinity | 1 | 2021 | 50 | 0.040 |
Why?
| | Biological Variation, Population | 1 | 2020 | 22 | 0.040 |
Why?
| | Time | 1 | 2020 | 85 | 0.040 |
Why?
| | Medicare Part C | 1 | 2021 | 38 | 0.040 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2020 | 141 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2020 | 289 | 0.040 |
Why?
| | Pyuria | 1 | 2020 | 5 | 0.040 |
Why?
| | Mitochondrial Proteins | 1 | 2022 | 263 | 0.040 |
Why?
| | Disease Management | 1 | 2024 | 649 | 0.040 |
Why?
| | Polypharmacy | 1 | 2021 | 94 | 0.040 |
Why?
| | Morbidity | 1 | 2021 | 317 | 0.040 |
Why?
| | Professional Role | 1 | 2021 | 171 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2024 | 1500 | 0.040 |
Why?
| | Catheters, Indwelling | 2 | 2010 | 94 | 0.040 |
Why?
| | Chromosome Mapping | 1 | 2021 | 505 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2024 | 705 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2022 | 456 | 0.040 |
Why?
| | Inappropriate Prescribing | 1 | 2020 | 66 | 0.040 |
Why?
| | Caenorhabditis elegans | 1 | 2022 | 329 | 0.040 |
Why?
| | Safety | 1 | 2020 | 346 | 0.030 |
Why?
| | Remission Induction | 1 | 2019 | 308 | 0.030 |
Why?
| | Transforming Growth Factor beta | 1 | 2021 | 466 | 0.030 |
Why?
| | Homeostasis | 1 | 2022 | 646 | 0.030 |
Why?
| | Seizures | 1 | 2022 | 489 | 0.030 |
Why?
| | Methotrexate | 1 | 2019 | 234 | 0.030 |
Why?
| | Saccharomyces cerevisiae | 1 | 2022 | 584 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2025 | 2228 | 0.030 |
Why?
| | Insurance Claim Reporting | 1 | 2017 | 25 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2025 | 3633 | 0.030 |
Why?
| | Clinical Coding | 1 | 2017 | 28 | 0.030 |
Why?
| | Education, Distance | 1 | 2018 | 59 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2026 | 2007 | 0.030 |
Why?
| | Base Sequence | 1 | 2021 | 2119 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2022 | 2533 | 0.030 |
Why?
| | Antirheumatic Agents | 1 | 2019 | 309 | 0.030 |
Why?
| | Societies, Medical | 1 | 2021 | 901 | 0.030 |
Why?
| | Aortography | 1 | 2016 | 52 | 0.030 |
Why?
| | Gene Expression | 1 | 2021 | 1461 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 1323 | 0.030 |
Why?
| | RNA | 1 | 2022 | 925 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1318 | 0.030 |
Why?
| | Survival Rate | 1 | 2020 | 2078 | 0.030 |
Why?
| | Population Surveillance | 1 | 2019 | 477 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1652 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 1062 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 6050 | 0.030 |
Why?
| | Interviews as Topic | 1 | 2018 | 926 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2021 | 3121 | 0.030 |
Why?
| | Coronary Artery Bypass | 1 | 2016 | 268 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2022 | 2591 | 0.020 |
Why?
| | Research Design | 1 | 2018 | 1139 | 0.020 |
Why?
| | Algorithms | 1 | 2020 | 1843 | 0.020 |
Why?
| | Prevalence | 1 | 2019 | 2852 | 0.020 |
Why?
| | Hospital Administration | 1 | 2010 | 25 | 0.020 |
Why?
| | Anticoagulants | 1 | 2016 | 743 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3396 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 2097 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 6021 | 0.020 |
Why?
| | Inservice Training | 1 | 2010 | 114 | 0.020 |
Why?
| | Problem Solving | 1 | 2010 | 154 | 0.020 |
Why?
| | Program Development | 1 | 2010 | 365 | 0.020 |
Why?
| | Signal Transduction | 1 | 2021 | 5234 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2008 | 567 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2010 | 467 | 0.020 |
Why?
| | Leadership | 1 | 2010 | 410 | 0.010 |
Why?
| | Risk | 1 | 2008 | 917 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 5875 | 0.010 |
Why?
| | Patient Care Team | 1 | 2010 | 700 | 0.010 |
Why?
| | Fractures, Bone | 1 | 2008 | 431 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2013 | 6449 | 0.010 |
Why?
|
|
Murphy's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|